ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
Targeting the tumor microenvironment with SRC kinase inhibition.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Decoding the Roles of Astrocytes and Hedgehog Signaling in Medulloblastoma.Current oncology (Toronto, Ont.) · 2021Review
- Hypoxic tumor microenvironment: Implications for cancer therapy.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.ACS medicinal chemistry letters · 2015Article
- Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines.BioImpacts : BI · 2014Review
- Vitexicarpin acts as a novel angiogenesis inhibitor and its target network.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.Clinical & experimental metastasis · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although most cancer therapies are directed against tumor cells, an emerging area of cancer therapeutics focuses on targeting cells of the tumor microenvironment. Inhibiting the Src family kinase with dasatinib decreases tumor growth through inhibiting growth of tumor-associated endothelial and myeloid cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.